Condition
Carcinoma, Merkel Cell
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed2
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07302347Phase 1Recruiting
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
NCT02471352Recruiting
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol
NCT02155647Phase 2CompletedPrimary
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
NCT02351128Phase 2CompletedPrimary
Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues
Showing all 4 trials